Equivalent Dose of Gliclazide for Glyburide (Glibenclamide)
Introduction to Sulfonylurea Equivalence
- 6 mg of glyburide (glibenclamide) is equivalent to approximately 80-120 mg of gliclazide, according to the American College of Clinical Endocrinologists 1
Sulfonylurea Equivalence and Considerations
- Glyburide has a longer duration of action and higher risk of hypoglycemia compared to gliclazide, which is why dose conversion must account for these differences, as noted by the American Diabetes Association 2, 3
- When converting between sulfonylureas, it's essential to consider that gliclazide has a more favorable safety profile, particularly in patients with renal impairment, as stated by the National Kidney Foundation 4, 5
Dosing Recommendations
- Gliclazide is preferred over glyburide in patients with renal impairment (eGFR <50 mL/min/1.73m²) due to lower risk of hypoglycemia, according to the American Journal of Kidney Diseases 4, 3
- Glyburide should be avoided in patients with GFR <30 mL/min/1.73m² as it is mainly renally excreted and can cause prolonged hypoglycemia, as warned by the National Kidney Foundation 4, 5
Clinical Considerations When Switching
- When switching from glyburide to gliclazide, start with a lower dose of gliclazide and titrate based on blood glucose response, as recommended by the American Diabetes Association 2, 1
- Gliclazide may be safer than glyburide in elderly patients, patients with renal impairment, and patients with cardiovascular disease, according to the American Heart Association and the National Kidney Foundation 3, 6, 4, 5
Dosing Equivalence Table
| Glyburide (Glibenclamide) | Gliclazide |
|---|---|
| 2.5 mg | 30-40 mg |
| 5 mg | 60-80 mg |
| 6 mg | 80-120 mg |
| 10 mg | 160-240 mg |
Common Pitfalls to Avoid
- Failing to adjust the dose when switching between sulfonylureas with different potencies and durations of action, as cautioned by the American Diabetes Association 1
- Not considering renal function when selecting the appropriate sulfonylurea, as emphasized by the National Kidney Foundation 4, 5, 6
- Overlooking the need for more frequent glucose monitoring during the transition period, as recommended by the American Diabetes Association 3
- Assuming equivalent hypoglycemic risk between different sulfonylureas (gliclazide has lower risk than glyburide), as noted by the American Diabetes Association 2, 3